²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Launched by FRED HUTCHINSON CANCER CENTER · Oct 5, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with high-risk multiple myeloma, which is a type of blood cancer. The treatment involves a special drug called ²¹¹At-OKT10-B10, which is designed to target and kill cancer cells, along with chemotherapy drugs and low-dose radiation therapy. This combination is given before a donor stem cell transplant, which is a procedure that helps replace unhealthy blood cells with healthy ones from a donor. The goal is to see how well this treatment works and to learn about any side effects it may cause.

To participate in this trial, patients should have newly diagnosed, recurrent, or treatment-resistant multiple myeloma and meet certain health criteria. For example, they need to have specific genetic features related to their cancer and must be able to start the treatment within a certain time after their last stem cell transplant. Participants can expect to receive this combination treatment and be closely monitored for any side effects. It's also important for patients to have a suitable donor for the stem cell transplant. Overall, this trial aims to find a potentially effective new treatment option for individuals facing a challenging cancer diagnosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with newly diagnosed or relapsed/refractory multiple myeloma
• * Patients with multiple myeloma must have at least one of the following high-risk features:
• • t(4;14), t(14;16), t(14;20) or deletion 17p, gain in chromosome 1q (\> 3 copies of CKS1b) by fluorescence in situ hybridization (FISH); hypodiploidy; complex karyotype
• • Revised International Staging System III
• • Plasmablastic morphology
• • History of primary or secondary plasma cell leukemia
• • Patients must start ²¹¹At-OKT10-B10 within 40-180 days of autologous stem cell transplant (either as part of their induction, or as salvage)
• • Patients must have an estimated creatinine clearance greater than 50/ml per minute measured by 24-hour urine collection
• • Total bilirubin \< 2 times the upper limit of normal
• • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2 times the upper limit of normal)
• • Patients must have an Eastern Cooperative Oncology Group (ECOG) =\< 2 or Karnofsky \>= 70
• • Patients must have CD38+ myeloma cells as demonstrated by either flow cytometry or immunohistochemistry in most recent bone marrow that had evidence of clonal plasma cells
• • For patients of childbearing potential, must have a negative urinary pregnancy test on the day of and prior to infusion of ²¹¹At-OKT10-B10
• • Ability to provide informed consent
• * Patients must have an HLA-matched related donor or an HLA-matched unrelated donor who meets standard Fred Hutchinson Cancer Center and/or National Marrow Donor Program (NMDP) or other donor center criteria for peripheral blood stem cell (PBSC) or bone marrow donation, as follows:
• • Related donor: related to the patient and genotypically or phenotypically identical for HLA-A, B, C, DRB1 and DQB1. Phenotypic identity must be confirmed by high-resolution typing
• * Unrelated donor:
• • Matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing; OR
• • Mismatched for a single allele without antigen mismatching at HLA-A, B, or C as defined by high resolution typing but otherwise matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing
• • Donors are excluded when preexisting immunoreactivity is identified that would jeopardize donor hematopoietic cell engraftment. The recommended procedure for patients with 10 of 10 HLA allele level (phenotypic) match is to obtain panel reactive antibody (PRA) screens to class I and class II antigens for all patients before HCT. If the PRA shows \> 10% activity, then flow cytometric or B and T cell cytotoxic cross matches should be obtained. The donor should be excluded if any of the cytotoxic cross match assays are positive. For those patients with an HLA class I allele mismatch, flow cytometric or B and T cell cytotoxic cross matches should be obtained regardless of the PRA results. A positive anti-donor cytotoxic crossmatch is an absolute donor exclusion
• • Patient and donor pairs homozygous at a mismatched allele in the graft rejection vector are considered a two-allele mismatch, i.e., the patient is A\*0101 and the donor is A\*0102, and this type of mismatch is not allowed
• • Patients without an HLA-matched related or unrelated donor available must have a related donor who is identical for one HLA haplotype and mismatched at the HLA-A, -B or DRB1 loci of the unshared haplotype with the exception of single HLA-A, -B or DRB1 mismatches
• Exclusion Criteria:
• • History of central nervous system involvement by multiple myeloma
• • Presence of circulating plasma cells in the peripheral blood of 5% or more by flow cytometry or morphology
• • Prior radioimmunotherapy or radiation of \> 20 Gy to pelvis or at maximally tolerated levels to any critical normal organ
• • Prior allogeneic HCT
• • More than two prior autologous HCTs
• • Patients with plasmacytomas \> 1 cm in bone marrow or any extramedullary plasmacytoma. Previously fludeoxyglucose F-18 (FDG) avid mass lesions by positron emission tomography (PET) that are no longer hypermetabolic following the most recent cycle of therapy are exempt, as are plasmacytomas irradiated with curative intent (\>= 35 Gy)
• • Patients with symptomatic coronary artery disease defined as having angina or anginal equivalent, and/or arrhythmias requiring anti-arrhythmics for rhythm control
• • History of reactive airway disease and clinically significant asthma requiring ongoing treatment
• * Patients with the following organ dysfunction:
• • Left ventricular ejection fraction \< 40% in patients with HLA-matched or unrelated donor or \< 45% in patients with an HLA-haploidentical donor
• • New York Heart Association (NYHA) class \> 1 heart failure
• • Corrected diffusing capacity of the lungs for carbon monoxide (DLCO) \< 50% or receiving supplemental continuous oxygen. When pulmonary function tests cannot be obtained, the 6-minute walk test (6MWT, also known as exercise oximetry) will be used: Any patient with oxygen saturation on room air of \< 90% during a 6MWT will be excluded
• • Liver abnormalities: fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction as evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis, or symptomatic biliary disease
• • Patients who are known to be seropositive for human immunodeficiency virus (HIV)
• • Perceived inability to tolerate diagnostic or therapeutic procedures
• • Women of childbearing potential who are pregnant (beta-human chorionic gonadotropin \[HCG\]+) or breast feeding
• • Fertile men and women unwilling to use contraceptives during and for 12 months post-transplant
• • Uncontrolled or untreated active infection
• • Patients with known AL subtype amyloidosis
• • Inability to understand or give an informed consent
• • Known allergy to murine-based monoclonal antibodies
• • Known contraindications to radiotherapy
• • History of another primary malignancy that has not been in remission for at least 2 years. The following are exempt from the 2-year-limit: nonmelanoma skin cancer, curatively treated localized prostate cancer, or cervical carcinoma in situ or squamous intraepithelial lesion on papanicolaou (PAP) smear
• • Therapy with anti-CD38 monoclonal antibody within 3 months of ²¹¹At-OKT10-B10 infusion
• • Prior therapy with radiolabeled monoclonal antibodies
• • Any history of treatment with checkpoint inhibitor/s